ArticleCancers2023

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.

Lisa B Leypoldt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.